Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Rapt Therapeutics, Inc. (RAPT)
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Rapt Therapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Rapt Therapeutics, Inc. since 2005.
The reporting company's ticker symbol is RAPT. The reporting company's CIK number is 1673772.
The total value of stock buying since 2005 is $20,395,200.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $0.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2019-11-04||Robbins Wendye (Director)||Buy||1,600||12.00||19,200|
|2019-11-04||Column Group Ii Management, Lp (10% Owner)||Buy||625,000||12.00||7,500,000|
|2019-11-04||Wong Brian Russell (President and CEO)||Buy||25,000||12.00||300,000|
|2019-11-04||Rieflin William Jl (Director)||Buy||8,000||12.00||96,000|
|2019-11-04||Goeddel David V (Director)||Buy||625,000||12.00||7,500,000|
Insider trading activities including stock purchases, stock sales, and option exercises of RAPT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Rapt Therapeutics, Inc. (symbol RAPT, CIK number 1673772) see the Securities and Exchange Commission (SEC) website.